McKesson (MCK) Upgraded to Buy: Here's What You Should Know

McKesson (MCK) just earned an upgrade to Zacks Rank #2 (Buy), driven by rising earnings estimates for the prescription drug distributor.

The Zacks Consensus Estimate for MCK has climbed 1.5% over the past three months. That revision trend places the stock in the top 20% of all Zacks-covered names for estimate changes, a ranking built specifically on the direction and magnitude of analyst earnings revisions.

Zacks frames the upgrade as a signal of improving business fundamentals and potential near-term share price appreciation. The logic is straightforward: the rank system treats upward estimate momentum as a leading indicator, on the premise that analysts raising forecasts reflect better underlying expectations for the company's profits.

A 1.5% move in consensus over three months is modest in absolute terms. Interpretation: the upgrade reflects steady, incremental estimate drift rather than a sharp earnings reset, so the signal is about direction and consistency, not a dramatic change in outlook. The top-20% placement is relative, meaning MCK's revisions are outpacing most of the covered universe.